Streetbeat News

LNSR

LENSAR, Inc.

https://www.lensar.com

Industry

Medical - Devices

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

LENSAR (NASDAQ:LNSR) reported Q2 2024 adjusted EPS of $(0.46), missing the $(0.29) estimate by 58.62%. Sales were $12.636M, beating the $12.150M estimate by 4.00%. EPS decreased by 76.92% YoY, while sales increased by 5.19% YoY.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:30 am

LENSAR announced that its ALLY Adaptive Cataract Treatment System has received certification under the European Union's Medical Device Regulation (MDR).

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:25 am

LENSAR (NASDAQ:LNSR) reported Q1 2024 earnings with a GAAP EPS of $(0.19), surpassing the $(0.28) estimate, and sales of $10.588M, slightly above the $10.550M estimate. This represents a significant improvement over the previous year, with a 52.5% decrease in losses per share and a 28.31% increase in sales.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 11:13 am

Lake Street has initiated coverage on LENSAR (NASDAQ:LNSR) with a Buy rating and set a price target of $8.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 5:40 pm

LENSAR (NASDAQ:LNSR) reported Q4 earnings with a per-share loss of $(0.35), missing the $(0.22) estimate, and sales of $12.11M, slightly above the $12.00M estimate. This represents a decrease in earnings and an increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:02 pm

Earnings reports for March 4, 2024, include a mix of expected losses and gains across various sectors. Notable companies like Sea, Global Ship Lease, and Stitch Fix are among those reporting, with projections ranging from significant losses to substantial earnings per share. This diverse earnings landscape provides insights into different industry performances.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 9:53 am

LENSAR (NASDAQ:LNSR) is scheduled to release its quarterly earnings report on Monday, 2024-03-04, with analysts expecting an EPS of $-0.22. The company's past performance shows mixed results, with the last quarter beating estimates by $0.11 and a subsequent 0.44% increase in share price. Over the last year, LNSR shares have risen by 56.42%, trading at $4.88 as of February 29. Investors are looking forward to not only the earnings results but also the company's guidance for future growth.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 3:02 pm

LENSAR (NASDAQ:LNSR) reported Q3 losses of $(0.23) per share, beating the analyst consensus estimate of $(0.34) by 32.35%. However, the company's quarterly sales of $9.79 million missed the analyst consensus estimate of $10.20 million by 3.97%. This represents a 26.42% increase over sales from the same period last year.

Portfolio Pulse from totan@benzinga.com

November 09, 2023 | 12:08 pm

Several stocks are experiencing significant pre-market trading movements. AgileThought, Inc. (AGIL), Digital Brands Group, Inc. (DBGI), NanoVibronix, Inc. (NAOV), Tingo Group, Inc. (TIO), Top KingWin Ltd. (TCJH), Aravive, Inc. (ARAV), 1847 Holdings LLC (EFSH), Dermata Therapeutics, Inc. (DRMA), Arcadia Biosciences, Inc. (RKDA), and Globalstar, Inc. (GSAT) are among the gainers. Outlook Therapeutics, Inc. (OTLK), FibroGen, Inc. (FGEN), MasterCraft Boat Holdings, Inc. (MCFT), Ambarella, Inc. (AMBA), Genius Group Limited (GNS), TD Holdings, Inc. (GLG), Tivic Health Systems, Inc. (TIVC), VAALCO Energy, Inc. (EGY), LENSAR, Inc. (LNSR), and OKYO Pharma Limited (OKYO) are among the losers.

Portfolio Pulse from Lisa Levin

August 30, 2023 | 1:14 pm

During Wednesday's pre-market session, several healthcare stocks experienced significant movements. NanoVibronix, Aravive, Dermata Therapeutics, AEON Biopharma, Akso Health Group, and Harvard Bioscience saw increases in their stock prices, while Outlook Therapeutics, FibroGen, OKYO Pharma, Tivic Health Systems, LENSAR, and Acorda Therapeutics experienced decreases.

Portfolio Pulse from Benzinga Insights

August 30, 2023 | 1:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.